Completed × Interventional × Lung Diseases × Clear all
NCT03037385 2025-05-31

ARROW

Hoffmann-La Roche

Phase 1/2 Completed
590 enrolled 58 charts 5 FDA
NCT04774952 2025-04-15

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Revolution Medicines, Inc.

Phase 1 Completed
58 enrolled
NCT03989115 2023-06-26

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Revolution Medicines, Inc.

Phase 1/2 Completed
113 enrolled 22 charts
NCT02897778 2022-04-28

Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors

Syndax Pharmaceuticals

Phase 1 Completed
30 enrolled
NCT02909452 2022-01-25

Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Syndax Pharmaceuticals

Phase 1 Completed
30 enrolled